Q4 2017 EPS Estimates for Aurinia Pharmaceuticals Inc Reduced by Analyst (AUP)
Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Stock analysts at Seaport Global Securities dropped their Q4 2017 EPS estimates for Aurinia Pharmaceuticals in a research report issued on Wednesday. Seaport Global Securities analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their previous estimate of ($0.05). Seaport Global Securities currently has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for Aurinia Pharmaceuticals’ FY2019 earnings at ($0.24) EPS and FY2020 earnings at ($0.11) EPS.
Aurinia Pharmaceuticals (AUP) opened at C$6.56 on Friday. Aurinia Pharmaceuticals has a 52 week low of C$2.75 and a 52 week high of C$14.17.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.